Back

Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure on replacement therapy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advancing heart failure diagnosis and management: insights from hemodynamics, inflammation, and emerging therapies Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Jong-Chan Youn

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul (Korea (Republic of))

4 More presentations in this session

Presentation thumbnail
Discrepancy in supine versus upright exercise hemodynamic testing and the impact on the diagnostic performance of H2FPEF and HFA-PEFF scores in patients with unexplained dyspnea
Doctor V. kittipibul (Durham, US)
Abstract Slides Video
Presentation thumbnail
Residual inflammation after myocardial infarction detected by somatostatin receptor PET predicts long-term adverse cardiac remodelling: findings of a parallel-design longitudinal cohort study
Doctor A. Corovic (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac resynchronization therapy: an enabler for GDMT optimization in HFrEF? Data from the Swedish Heart Failure and the Swedish Pacemaker and Implantable Cardioverter-Defibrillator Registries.
Doctor D. Tomasoni (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
Mitral regurgitation in patients with heart failure and reduced ejection fraction and clinical outcomes: Insights from GALACTIC-HF
Doctor M. Chimura (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Advancing heart failure diagnosis and management: insights from hemodynamics, inflammation, and emerging therapies
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Renin-angiotensin-aldosterone system inhibitor discontinuation and its impact on one-year mortality in heart failure patients with acute kidney injury: a propensity matched analysis
thumbnail
Congress Presentation
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.
thumbnail
Congress Presentation
Close: heart failure care in 2025 and beyond

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources